Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
Status:
Withdrawn
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
In this study, non-operable esophagogastric adenocarcinoma cancer patients or non-operable
biliary cancer patients whose cancer progressed/spread/got worse after first line treatment
will be treated with or without immunotherapy and chemotherapy. This study will take place in
several countries across Europe. One hundred twenty-three (123) patients will be invited to
participate in this study
Biliary tract cancer (BTC), is a form of cancer that start in your bile ducts, a series of
tubes that runs from the liver to the small intestines. It is not know yet the exact cause of
BTC. For patients who have advanced or metastatic BTC (where surgery is not possible),
chemotherapy is the first option for treatment. Chemotherapy with cisplatin and gemcitabine
(CisGem) is the current standard of care.
Esophagogastric cancer (EGC) is cancer that occurs in the esophagus, a long hollow tube that
runs from your throat to your stomach. The accumulating abnormal cells form a tumor in the
esophagus that can grow to invade nearby structures and spread to other parts of the body.
It's thought that chronic irritation of your esophagus may contribute to the changes that
cause esophageal cancer.
The purpose of this study is to look at the risks and benefits of combining DKN-01 and
atezolizumab (humanized monoclonal antibody) with or without paclitaxel (chemotherapy).
Immune therapy boosts the body's natural defenses to fight cancer. It uses specific products
made either by participants' body or in a laboratory to improve, target or restore immune
system function and control or stop cancer. Atezolizumab is such an "immunotherapy" drug.
DKN-01 is another new type of drug (humanized monoclonal antibody) in development as
anticancer agent. Paclitaxel is a commonly-used chemotherapy drug of the class of taxanes
used to treat a number of cancer types, it stimulates the cell to die or to stop the cell
from dividing into two new cells.The idea behind combining these drugs is linked to targeting
the immune system to attack the tumor. Combining immune and chemotherapy has already
demonstrated clinical activity in relapsed (return of the disease)/refractory (not responding
to treatment) esophagogastric cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC